Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase

IF 3.1 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-07-31 DOI:10.1002/cam4.71112

Daniele Caracciolo, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone

{"title":"Impact of COVID-19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase","authors":"Daniele Caracciolo, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone","doi":"10.1002/cam4.71112","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The COVID-19 pandemic significantly increased mortality risks for individuals with hematological malignancies.</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>We conducted a single-center observational study, focusing on the late pandemic phase of the infection (2022–2023), to identify risk factors associated with COVID-19 outcomes in vaccinated patients with hematological malignancies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Eighty-five COVID-19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non-Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID-19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID-19-related mortality rate was 22.4%, with a 30-day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Our data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS-CoV-2 infection.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 15","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.71112","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.71112","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The COVID-19 pandemic significantly increased mortality risks for individuals with hematological malignancies.

Patients and Methods

We conducted a single-center observational study, focusing on the late pandemic phase of the infection (2022–2023), to identify risk factors associated with COVID-19 outcomes in vaccinated patients with hematological malignancies.

Results

Eighty-five COVID-19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non-Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID-19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID-19-related mortality rate was 22.4%, with a 30-day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.

Conclusion

Our data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS-CoV-2 infection.

Abstract Image

查看原文本刊更多论文

COVID-19对血液病癌症患者的影响：来自大流行后期的见解

背景COVID-19大流行显著增加了血液系统恶性肿瘤患者的死亡风险。患者和方法我们开展了一项单中心观察性研究，重点关注感染的大流行晚期（2022-2023），以确定与接种疫苗的血液系统恶性肿瘤患者COVID-19结局相关的危险因素。结果血液学恶性肿瘤患者中新冠肺炎确诊病例85例，主要为多发性骨髓瘤（MM）（38.8%）、慢性淋巴细胞白血病（CLL）（10.6%）和非霍奇金淋巴瘤（NHL）（35.3%）。尽管COVID-19疫苗接种率很高（97.6%），但23.5%的患者发生了重症/危重症。总体covid -19相关死亡率为22.4%，30天死亡率为11.8%。尽管在观察期间死亡率显著下降（27.7% vs. 16.7%），但在重症感染携带者中并未证实这一趋势。结论：我们的数据证实，尽管随着时间的推移，重症感染和总死亡率有所下降，但在SARS-CoV-2感染的流行阶段，血液系统恶性肿瘤患者仍然处于高风险状态。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.